If your prompts influence policy, finance or patient care but live in chat threads, you don’t have innovation — you have unmanaged risk.
Sarepta Therapeutics has followed through on its promise to file for accelerated approval of its gene therapy SRP-9001 for Duchenne muscular dystrophy (DMD), as it aims for a launch in the middle of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results